Click any tag below to further narrow down your results
Links
The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.
The article shows U.S. office visits remain at about 70% of pre-pandemic levels, driving high vacancy rates and a flight to newer buildings. It also highlights research linking remote work—not AI—to rising youth unemployment, explores AI uptake among small employer firms versus solopreneurs, and details how emerging biotechs now lead in clinical trials and drug approvals.